Ackova Darinka Gjorgieva, Kanjevac Tatjana, Rimondini Lia, Bosnakovski Darko
Faculty of Medical Sciences, University "Goce Delcev" Stip, Krste Misirkov bb, 2000 Stip, R. Macedonia.
Recent Pat Anticancer Drug Discov. 2016;11(1):98-111. doi: 10.2174/1574892811666151111142721.
Understanding and apprehension of the characteristics and circumstances in which mesenchymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery systems, but also for making forward movement in the existing knowledge of involvement of major factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is reliable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses' directly at the tumor site (targeted chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems based on MSCs.
了解和认识间充质干细胞（MSCs）影响和改变（增强或降低）肿瘤生长及转移扩散的特征和情况至关重要，这不仅关乎将MSCs用作药物递送系统的可能性，还关乎在致癌过程中主要因素（肿瘤微环境、可溶性信号分子等）参与的现有知识方面取得进展。这种能力是可靠的，因为MSCs为设计针对癌症的新系统提供了很好的基础，这些新系统旨在在肿瘤区域分泌治疗性蛋白质，或直接在肿瘤部位递送溶瘤病毒（通过酶前药转化进行靶向化疗或诱导肿瘤细胞凋亡）。MSCs作为肿瘤周围环境的关键部分及其已证实的肿瘤嗜性，被认为是设计有前景的药物递送系统的一个开放途径。本文综述了该领域的当前出版物，找出了2012年后发表的最新专利（WO2014066122、US20140017787、WO2015100268、US20150086515），并试图展示基于MSCs的抗癌药物递送系统设计与开发的当前进展和未来前景。
